Ambeed.cn

首页 / 抑制剂/激动剂 / 蛋白质酪氨酸激酶(Protein Tyrosine Kinase) / Tie-2

货号 产品名 纯度
A1364854 Razuprotafib

98%
A253059 Tie2 kinase inhibitor 1

Tie2 kinase inhibitor is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM, 200-fold more potent than p38.

99%+
A200488 Cabozantinib/卡博替尼

Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.

98%
A209718 MGCD-265 analog

MGCD-265, an ATP-competitive inhibitor, can inhibit c-Met and VEGFR1, 2, 3 with IC50s of 1 nM and 3 nM, 3 nM, 4 nM, respectively. It also exhibits inhibition of Ron and Tie2.

99%+
A189540 Pexmetinib

Pexmetinib is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line.

99%+
A429803 CE-245677

CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases with a cellular IC50s of 4.7 and 1 nM.

97%
A614706 TIE-2/VEGFR-2 kinase-IN-1

99%
A378967 BAY-826

BAY-826 is a selective and potent TIE-2 inhibitor with Kdof 1.6 nM, respectively.

98%
A1328057 SB-633825

98%
A407333 Tie2 kinase inhibitor 2

97+%
A1964354 MDM2/XIAP-IN-1

95%
A2318408 TIE-2/VEGFR-2 kinase-IN-4

98%
A676324 TIE-2/VEGFR-2 kinase-IN-2

95+%
A2318405 TIE-2/VEGFR-2 kinase-IN-5

98%
A1964196 Zansecimab

95%
A1258164 GW768505A

GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2, with a pIC50 of 7.81 for VEGFR2. GW768505A free base has anti-angiogenic activity[1]。

98%
A1671305 Regorafenib mesylate

98%
A2318406 TIE-2/VEGFR-2 kinase-IN-3

98%
产品名 Tie-2 其他靶点 纯度
Tie2 kinase inhibitor 1 ++

Tie-2, IC50: 0.25 μM

99%+
MGCD-265 analog +++

Tie-2, IC50: 7 nM

99%+
Pexmetinib p38 MAPK 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
客户支持
专业术语
缩略词释义
质量手册
产品咨询
计算器
活动政策
订购方法
活动声明
联系我们
400-920-2911 sales@ambeed.cn tech@ambeed.cn
Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。